Drug interactions
Ipilimumab + Ponesimod
Severity: Moderate
Ipilimumab and Ponesimod: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ponesimod lowers circulating lymphocyte counts, while ipilimumab enhances T-cell activation and frequently causes immune-related toxicities that may need immunosuppressive treatment. Combining them may produce unpredictable immune effects, including higher infection risk or reduced antitumor activity. Clinical data are limited.
What this interaction means in plain words
Ipilimumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Ipilimumab belongs to Oncology; Ponesimod belongs to Central Nervous System.
Why it happens
Ponesimod sequesters lymphocytes via S1P receptor modulation, which may oppose the T-cell activation produced by CTLA-4 blockade.
What to do
Avoid combining unless clearly necessary. If used together, monitor lymphocyte counts and for infection or immune-related adverse events.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Ipilimumab and Ponesimod, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ipilimumab
Other interactions of Ponesimod
- Fingolimod + Ponesimod Contraindicated
- Ponesimod + Siponimod Contraindicated
- Amiodarone + Ponesimod Major
- Amisulpride + Ponesimod Major
- Anagrelide + Ponesimod Major
- Anti-thymocyte + Ponesimod Major
Frequently asked questions
Can I take Ipilimumab with Ponesimod?
MediHelp rates the interaction as moderate. Ipilimumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponesimod lowers circulating lymphocyte counts, while ipilimumab enhances T-cell activation and frequently causes immune-related toxicities that may need immunosuppressive treatment. Combining them may produce unpredictable immune effects, including higher infection risk or reduced antitumor activity. Clinical data are limited.
How serious is the interaction between Ipilimumab and Ponesimod?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining unless clearly necessary. If used together, monitor lymphocyte counts and for infection or immune-related adverse events.
What other medicines interact with Ipilimumab?
MediHelp also lists interactions of Ipilimumab with, for example, Etrasimod, Vemurafenib, Ciltacabtagene autoleucel. The full list is on the Ipilimumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
